Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IFN-γ increases δ-globin gene expression through activation of the JAK/STAT pathway in erythroid cells.

Blood·2025

Same author

Olfactomedin 4 in cancer development and progression.

Biochimica et biophysica acta. Reviews on cancer·2025

Same author

Differential MicroRNA Profiles Associated With the Hydroxyurea-Inducible <i>SAR1A</i> Gene.

Journal of hematology·2025

Same author

NIDDK: Celebrating 75 Years of Advancing Diabetes Research.

Diabetes care·2025

Same author

NIDDK: Celebrating 75 Years of Advancing Diabetes Research.

Diabetes·2025

Same author

Olfactomedin 4 promotes gastric cancer cell G2/M progression and serves as a therapeutic target in gastric adenocarcinoma.

Carcinogenesis·2025

Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026

Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026

Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026

Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026

Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026

Same journal

From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 12, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Illuminating the druggable genome: Pathways to progress.

Karlie R Sharma¹, Christine M Colvis¹, Griffin P Rodgers²

¹National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd, Bethesda, MD 20892, USA.

Drug Discovery Today

|October 27, 2023

Summary

This summary is machine-generated.

The Illuminating the Druggable Genome Program developed resources to study under-targeted proteins. These tools aim to advance research in G protein-coupled receptors, ion channels, and kinases for better human health outcomes.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Experiment Videos

Last Updated: Jul 12, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Area of Science:

Genomics
Proteomics
Drug Discovery

Background:

The human genome contains ~4500 druggable genes, but only a fraction are targeted by existing drugs.
Many druggable proteins, particularly G protein-coupled receptors (GPCRs), ion channels, and kinases, remain understudied.
The US National Institutes of Health initiated the Illuminating the Druggable Genome Program to address this knowledge gap.

Purpose of the Study:

To review and present resources created by the Illuminating the Druggable Genome Program.
To empower the scientific community to investigate understudied biological targets.
To accelerate the discovery of new therapeutics with the potential to impact human health.

Main Methods:

This review synthesizes outcomes and resources from the Illuminating the Druggable Genome Program.
The program focused on generating data and tools for three key protein families: GPCRs, ion channels, and kinases.
Resources are designed for broad accessibility and application by researchers.

Main Results:

The program has yielded a suite of valuable resources for studying under-targeted proteins.
These resources facilitate deeper exploration of the biology of GPCRs, ion channels, and kinases.
The developed tools are intended to bridge the gap between understudied genes and therapeutic development.

Conclusions:

The Illuminating the Druggable Genome Program has provided essential tools for advancing research in key protein families.
These resources will enable scientists to explore previously understudied areas of biology.
The program's output is poised to significantly contribute to the development of novel human health interventions.